NTRK2 and metastatic neoplasm: Furthermore, high NTRK2 expression showed association with shorter overall and disease-free survival (OS log-rank test: X2 = 6.126, p = 0.013; DFS log-rank test: X2 = 11.234, p < 0.001) in univariate analysis (irrespective of CRC cohort), but these associations were not independent of tumour, nodal or metastatic disease stages.